The evidence that link Metabolic Syndrome (MS) risks and Breast Cancer (BC) is highly controversial. This study was carried out to evaluate the MS among a group of newly and recently-diagnosed BC Jordanian women, according to harmonized criteria using the Jordanian cut-off points of obesity. A total of 396 BC patients aged 30–65 years attending BC clinics at the Jordanian Royal Medical Services in Jordan for management and follow-up of their conditions were screened for the presence of MS using the harmonized criteria. They were either newly-diagnosed before any medical intervention (n=134) or recently-diagnosed who received medical intervention during the first 3 months of diagnosis (n=262) BC patients. The latter were sub divided into chemo (n=176) and non-chemo (n=86) sub-groups. Pre-and postmenopausal status and BC severity [early stage (n=189) and advanced stage (n=207)] of BC patients were also studied. The MS prevalence in the whole BC patients using harmonized cut-off points (64.1%) was higher than that using Jordanian group cut-off points (52.0%). The MS was more prevalent, but insignificant, in recently-diagnosed (66.0%) than newly-diagnosed patients (60.0%). The MS prevalence was associated with increased severity of BC; it was 67.1% in advanced stage and 60.8% in early stage. The risk of MS in postmenopausal BC patients was higher (34.8%) than premenopausal (29.3%) patients. The risk of MS was increased with age. According to aforementioned results, it could be concluded that MS was markedly prevalent among BC patients. The MS prevalence tended to be higher among recently-diagnosed than newly-diagnosed BC patients using the harmonized definition, however, this prevalence decreased when the Jordanian group cut-off points were used. The MS was more prevalent in postmenopausal than premenopausal BC patients and it was associated with increased BC severity.
Published Date: 2019-06-11; Received Date: 2019-04-22